A potential new prodrug for the treatment of cystinosis:Design, synthesis and in-vitro evaluation

Bridgeen McCaughan, Graeme Kay, Rachel M Knott, Donald Cairns

    Research output: Contribution to journalArticle

    16 Citations (Scopus)

    Abstract

    Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in thecells of most organs. The disorder is treated by regular administration of the aminothiol, cysteamine, an odiferous and unpleasanttasting compound that along with its metabolites is excreted in breath and sweat, leading to poor patient compliance. In an attemptto improve patient compliance a series of novel prodrugs has been designed and evaluated as a potential new treatment for nephropathiccystinosis. The first of the prodrugs tested, 3a, was found to decrease the levels of intracellular cystine in cystinotic fibroblasts.This is the first report of a potential new therapeutic treatment for nephropathic cystinosis since the advent of cysteaminebitartrate.
    LanguageEnglish
    Pages1716-1719
    JournalBioorganic & Medicinal Chemistry Letters
    Volume18
    DOIs
    Publication statusPublished - 12 Jan 2008

    Fingerprint

    Cystinosis
    Cystine
    Prodrugs
    Patient Compliance
    Cysteamine
    Sweat
    Fibroblasts
    In Vitro Techniques
    Therapeutics

    Cite this

    @article{50dde1755b0f4fc3a1decc3f9cbf48ba,
    title = "A potential new prodrug for the treatment of cystinosis:Design, synthesis and in-vitro evaluation",
    abstract = "Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in thecells of most organs. The disorder is treated by regular administration of the aminothiol, cysteamine, an odiferous and unpleasanttasting compound that along with its metabolites is excreted in breath and sweat, leading to poor patient compliance. In an attemptto improve patient compliance a series of novel prodrugs has been designed and evaluated as a potential new treatment for nephropathiccystinosis. The first of the prodrugs tested, 3a, was found to decrease the levels of intracellular cystine in cystinotic fibroblasts.This is the first report of a potential new therapeutic treatment for nephropathic cystinosis since the advent of cysteaminebitartrate.",
    author = "Bridgeen McCaughan and Graeme Kay and Knott, {Rachel M} and Donald Cairns",
    year = "2008",
    month = "1",
    day = "12",
    doi = "10.1016/j.bmcl.2008.01.039",
    language = "English",
    volume = "18",
    pages = "1716--1719",
    journal = "Bioorganic and Medicinal Chemistry",
    issn = "0968-0896",
    publisher = "Elsevier",

    }

    A potential new prodrug for the treatment of cystinosis:Design, synthesis and in-vitro evaluation. / McCaughan, Bridgeen; Kay, Graeme; Knott, Rachel M; Cairns, Donald.

    In: Bioorganic & Medicinal Chemistry Letters, Vol. 18, 12.01.2008, p. 1716-1719.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A potential new prodrug for the treatment of cystinosis:Design, synthesis and in-vitro evaluation

    AU - McCaughan, Bridgeen

    AU - Kay, Graeme

    AU - Knott, Rachel M

    AU - Cairns, Donald

    PY - 2008/1/12

    Y1 - 2008/1/12

    N2 - Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in thecells of most organs. The disorder is treated by regular administration of the aminothiol, cysteamine, an odiferous and unpleasanttasting compound that along with its metabolites is excreted in breath and sweat, leading to poor patient compliance. In an attemptto improve patient compliance a series of novel prodrugs has been designed and evaluated as a potential new treatment for nephropathiccystinosis. The first of the prodrugs tested, 3a, was found to decrease the levels of intracellular cystine in cystinotic fibroblasts.This is the first report of a potential new therapeutic treatment for nephropathic cystinosis since the advent of cysteaminebitartrate.

    AB - Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in thecells of most organs. The disorder is treated by regular administration of the aminothiol, cysteamine, an odiferous and unpleasanttasting compound that along with its metabolites is excreted in breath and sweat, leading to poor patient compliance. In an attemptto improve patient compliance a series of novel prodrugs has been designed and evaluated as a potential new treatment for nephropathiccystinosis. The first of the prodrugs tested, 3a, was found to decrease the levels of intracellular cystine in cystinotic fibroblasts.This is the first report of a potential new therapeutic treatment for nephropathic cystinosis since the advent of cysteaminebitartrate.

    U2 - 10.1016/j.bmcl.2008.01.039

    DO - 10.1016/j.bmcl.2008.01.039

    M3 - Article

    VL - 18

    SP - 1716

    EP - 1719

    JO - Bioorganic and Medicinal Chemistry

    T2 - Bioorganic and Medicinal Chemistry

    JF - Bioorganic and Medicinal Chemistry

    SN - 0968-0896

    ER -